The antiviral Sofosbuvir against mucormycosis: An in silico perspective

Future Virology

Volumn 14, Issue 11, 2019, Pages 739-744

  Elfiky, Abdo A ^a,b  

^a CAIRO UNIVERSITY   (Egypt)

^b JOUF UNIVERSITY   (Saudi Arabia)

Author keywords

HCV; molecular docking; mucormycosis; RNA dependent RNA polymerase; Sofosbuvir

Indexed keywords

ASPARTIC ACID; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; SOFOSBUVIR; URIDINE TRIPHOSPHATE;

ARTICLE; COMPUTER MODEL; DRUG PROTEIN BINDING; MOLECULAR DOCKING; MUCORMYCOSIS; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; RHIZOPUS ORYZAE;

EID: 85077906898     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl-2019-0076     Document Type: Article

References (31)

1. Lehrer RI, Howard DH, Sypherd PS, Edwards JE, Segal GP, Winston DJ. Mucormycosis. Ann. Intern. Med. 93(1), 93-108 (1980).
2. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis. 54(Suppl. 1), S23-S34 (2012).
3. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18(3), 556-569 (2005).
4. Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis - the bitter and the sweet. PLoS Pathog. 13(8), e1006408 (2017).
5. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv. Ophthalmol. 39(1), 3-22 (1994).
6. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch. Intern. Med. 159(12), 1301-1309 (1999).
7. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin. Infect. Dis. 54(Suppl. 1), S16-S22 (2012).
8. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 89(2), 207-214 (2004).
9. Gebremariam T, Wiederhold NP, Alqarihi A et al. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. J. Antimicrob. Chemother. 72(2), 462-466 (2016).
10. Doublie S, Ellenberger T. The mechanism of action of T7 DNA polymerase. Curr. Opin. Struct. Biol. 8(6), 704-712 (1998).
11. Elfiky AA, Gawad A, Elshemey M. Hepatitis C viral polymerase inhibition using directly acting antivirals, a computational approach. Software Techn. Bio-Mol. Model. 13, 197-208 (2016).
12. Ferrer-Orta C, Ferrero D, Verdaguer N. RNA-Dependent RNA polymerases of picornaviruses: from the structure to regulatory mechanisms. Viruses 7(8), 4438-4460 (2015).
13. Yang PL, Gao M, Lin K, Liu Q, Villareal VA. Anti-HCV drugs in the pipeline. Curr. Opin. Virol. 1(6), 607-616 (2011).
14. Mayhoub AS. Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorg. Med. Chem. 20(10), 3150-3161 (2012).
15. Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J. Med. Virol. 89(6), 1040-1047 (2017).
16. Elfiky AA. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J. Med. Virol. 88(12), 2044-2051 (2016).
17. Leach A. Molecular Modelling: Principles and Applications (2nd Edition). Prentice Hall, Harlow, England (2001).
18. Saleh NA. The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors. Spectrochim. Acta, Part A 136(C), 1523-1529 (2014).
19. Talele TT, Arora P, Kulkarni SS et al. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. 18(13), 4630-4638 (2010).
20. Elfiky AA, Elshemey WM, Gawad WA. 2-methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and Ribavirin in hepatitis C virus inhibition: a molecular modeling study. J. Comput. Theor. Nanosci. 12(3), 376-386 (2015).
21. National Center of Biotechnology Informatics (NCBI) (2019). www. ncbi. nlm. nih. gov/
22. Biasini M, Bienert S, Waterhouse A et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 42(W1), W252-W258 (2014).
23. SAVES v5. 0. Structural analysis and verification (2017). https://servicesn. mbi. ucla. edu/SAVES/
24. Laskowski RA, Rullmann JAC, MaCarthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8(4), 477-486 (1996).
25. Hooft RW, Vriend G, Sander C, Abola EE. Errors in protein structures. Nature 381(6580), 272 (1996).
26. Lii JH, Allinger NL. Molecular mechanics. The MM3 force field for hydrocarbons. 3. The van der Waals' potentials and crystal data for aliphatic and aromatic hydrocarbons. J. Am. Chem. Soc. 111(23), 8576-8582 (1989).
27. Summers KL, Mahrok AK, Dryden MD, Stillman MJ. Structural properties of metal-free apometallothioneins. Biochem. Biophys. Res. Commun. 425(2), 485-492 (2012).
28. Morris GM, Huey R, Lindstrom W et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30(16), 2785-2791 (2009).
29. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455-461 (2010).
30. The PyMOL Molecular Graphics System, Version 1. 7. 6 Schrödinger, LLC (2019). https://pymol. org/2/
31. Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nat. Struct. Mol. Biol. 10(12), 980-980 (2003).